Wockhardt posts Q3 net profit at Rs. 20 Cr

Wockhardt also saw its revenue from operations increased 3% to Rs. 721 crore during Q3 FY25

Aurbindo Pharma posts Q3 FY25 profit at Rs. 846 Cr

During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.

Nectar Lifesciences posts Q3 FY25 PAT at Rs. 7.84 Cr

Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,

Biocon posts Q3 FY25 PAT at Rs. 25 Cr

The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars

Enhertu approved in US for breast cancer post more endocrine therapies

Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year

Supriya Lifescience posts Q3 FY25 PAT up at Rs. 46.78 Cr

The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments

Torrent Pharmaceuticals posts Q3 FY25 consolidated PAT at Rs. 503 Cr

Torrent Pharmaceuticals has reported total income of Rs. 2,842 crores during the period ended December 31, 2024

RPG Life Sciences posts Q3 FY25 PAT higher at Rs. 34.93 Cr

RPG Life Sciences has reported total income of Rs. 176.02 crore during the period ended December 31, 2024

Laurus Labs posts Q3 FY25 consolidated PAT higher at Rs. 92.30 Cr

Laurus Labs has reported total income of Rs. 1,424.47 crores during the period ended December 31, 2024

Lupin Digital Health partners with Medicover Hospitals for post discharge cardiac care